Drugs / CD8+NKG2D+ AKT Cell
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 0 | NCT02929797 | Aug 2016 → Aug 2017 | pancreatic ductal adenocarcinoma | Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CD8+NKG2D+ AKT Cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02929797 ↗ |
| Modality | Cell therapy | “CD8+NKG2D+ AKT cell immunotherapy” NCT02929797 ↗ |